RxDoctor Payments Data

Ritesh Ramdhani, MD

Neurology · New York, NYNPI 1922232339

Payments from drug & device makers

$521,492in general payments, 2019–2025

Across 187 payments — averaging $2788.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$353K
  • Boston Scientific$93K
  • Global Kinetics USA Corporation$23K
  • Genentech, Inc.$21K
  • Abbott$14K
  • Travere Therapeutics, Inc.$9K
  • plus $8K from 4 others

What the payments were for

  • Consulting fees$1,84018%
  • Speaking & faculty fees$4,45045%
  • Travel & lodging$2462%
  • Food & beverage$3,46135%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$521,492 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$146,606
Medicare patients
400
Services billed
2,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl82$387,196
NuplazidPimavanserin Tartrate54$275,969
RytaryCarbidopa/Levodopa137$157,316
IngrezzaValbenazine Tosylate18$140,653
NeuproRotigotine58$93,922
InbrijaLevodopa13$42,297
Tetrabenazine34$33,431
XadagoSafinamide Mesylate11$28,396
Carbidopa-LevodopaCarbidopa/Levodopa681$26,494
Rasagiline Mesylate77$19,905
FycompaPerampanel13$18,851
Carbidopa21$13,431
Entacapone55$12,805
Carbidopa-Levodopa ErCarbidopa/Levodopa386$11,067
Rivastigmine50$10,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$3,695$387,19682 claims
Amneal Pharmaceuticals LLCRytary$1,326$157,316137 claims
Acorda Therapeutics, IncInbrija$1,365$42,29713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →